Amesite Inc.
For the period ended Mar 31, 2026. Filed May 18, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 18, 2026
AMST$0.48-9.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
| For the Nine Months Ended | |||
|---|---|---|---|
| March 31, | |||
| 2026 · 2025 | |||
| Cash Flows from Operating Activities | |||
| Net Loss | $(2,052,875) | $(2,693,100) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 199,553 | 331,719 | |
| Stock-based compensation expense | 216,756 | (38,174) | |
| Allowance for doubtful accounts | 7,964 | - | |
| Warrants issued for underwriting fee | - | 95,984 | |
| Changes in operating assets and liabilities which used cash: | |||
| Accounts receivable | (20,598) | 25,620 | |
| Prepaid expenses and other current assets | (68,193) | 227,768 | |
| Accounts payable | (7,104) | (17,970) | |
| Accrued compensation | 324,500 | 133,799 | |
| Deferred revenue | (32,770) | 3,835 | |
| Other accrued liabilities | (53,240) | (85,285) | |
| Net cash and cash equivalents used in operating activities | (1,486,007) | (2,015,804) | |
| Cash Flows from Investing Activities | |||
| Investment in capitalized software | (206,700) | (292,199) | |
| Net cash and cash equivalents used in investing activities | (206,700) | (292,199) | |
| Cash Flows from Financing Activities | |||
| Proceeds from the sale of common stock | - | 3,095,950 | |
| Net cash and cash equivalents provided by financing activities | - | 3,095,950 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (1,692,707) | 787,947 | |
| Cash, cash equivalents, and restricted cash - Beginning of period | 2,433,418 | 2,171,016 | |
| Cash, cash equivalents, and restricted cash - End of period | $740,711 | $2,958,963 | |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES: | |||
| Settle restricted stock units through common stock issuance to directors | $400,000 | $600,000 | |
| Issuance of common stock for accrued director compensation | $ | - | $21,890 |
| Issuance of common stock for public offering consulting expenses | $ | - | $655,000 |
-6-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.